Wangchen Tsering
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wangchen Tsering has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Stefan Prokop
University of Florida, Gainesville, FL, USA
2 shared publications- Alejandra Jolie Ruiz
Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, USA
1 shared publication - Angelica Maria Ruiz
Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, USA
1 shared publication - Benoit I. Giasson
Department of Neuroscience, University of Florida, Gainesville, USA
1 shared publication - David R. Borchelt
Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida
1 shared publication - Guilian Xu
Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, USA
1 shared publication
Latest Publications
- Open Access
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S1) , e104912
Brain region‐specific accumulation of amyloidosis‐associated proteins in postmortem brain tissues of Alzheimer's disease patients
Background: The matrisome is a comprehensive list of molecules that form and interact with the extracellular matrix (ECM). The matrisome includes not only structural proteins but also signaling molecules and regulators that that can modify the ECM. Proteomic studies in human and animal models of Alzheimer's disease (AD) have shown alterations in matrisome proteins in AD. We previously showed that some of the matrisome proteins increase during the progression of AD and can modify Aβ plaques and cerebral amyloid angiopathy (CAA). However, the role of these proteins in AD pathogenesis and their characterization in postmortem brain tissue remain unclear. Method: We employed a detailed immunohistochemistry study on postmortem brain tissues representing different neuropathological changes, namely Low AD ( n = 6), Intermediate AD ( n = 6), and High AD cases ( n = 6), to elucidate the accumulation of five matrisome proteins (MDK, SPOCK3, Col25a1, SDC4 and EGFL8) in four different brain regions (the occipital cortex, hippocampus, striatum, and cerebellum), and their association with Aβ plaques, neurofibrillary tangles (NFT), and CAA. Result: We found that all matrisome proteins increase with the disease progression in the occipital cortex and hippocampus. Interestingly, similar to Aβ plaque, MDK staining was observed in all brain regions examined, while SPOCK3, Col25a1, EGFL8, and SDC4 staining were rare in the striatum and completely absent in the cerebellum. SPOCK3 staining shows region‐specific vulnerability, with a significantly higher burden in the hippocampus compared to other brain regions. All matrisome proteins stain only a subset of Aβ plaques. The colocalization and staining patterns of matrisome proteins suggest that some of these proteins may mediate tau spreading and represent different phases of Aβ deposition. Conclusion: Overall, our results suggest that matrisome proteins can influence the Aβ deposition, serve as biomarkers for AD, and can offer a new avenue for developing drugs that target matrisome proteins.
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S1) , e104912
Open AccessBrain region‐specific accumulation of amyloidosis‐associated proteins in postmortem brain tissues of Alzheimer's disease patients
Background: The matrisome is a comprehensive list of molecules that form and interact with the extracellular matrix (ECM). The matrisome includes not only structural proteins but also signaling molecules and regulators that that can modify the ECM. Proteomic studies in human and animal models of Alzheimer's disease (AD) have shown alterations in matrisome proteins in AD. We previously showed that some of the matrisome proteins increase during the progression of AD and can modify Aβ plaques and cerebral amyloid angiopathy (CAA). However, the role of these proteins in AD pathogenesis and their characterization in postmortem brain tissue remain unclear. Method: We employed a detailed immunohistochemistry study on postmortem brain tissues representing different neuropathological changes, namely Low AD ( n = 6), Intermediate AD ( n = 6), and High AD cases ( n = 6), to elucidate the accumulation of five matrisome proteins (MDK, SPOCK3, Col25a1, SDC4 and EGFL8) in four different brain regions (the occipital cortex, hippocampus, striatum, and cerebellum), and their association with Aβ plaques, neurofibrillary tangles (NFT), and CAA. Result: We found that all matrisome proteins increase with the disease progression in the occipital cortex and hippocampus. Interestingly, similar to Aβ plaque, MDK staining was observed in all brain regions examined, while SPOCK3, Col25a1, EGFL8, and SDC4 staining were rare in the striatum and completely absent in the cerebellum. SPOCK3 staining shows region‐specific vulnerability, with a significantly higher burden in the hippocampus compared to other brain regions. All matrisome proteins stain only a subset of Aβ plaques. The colocalization and staining patterns of matrisome proteins suggest that some of these proteins may mediate tau spreading and represent different phases of Aβ deposition. Conclusion: Overall, our results suggest that matrisome proteins can influence the Aβ deposition, serve as biomarkers for AD, and can offer a new avenue for developing drugs that target matrisome proteins.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e092565
Accumulation of Novel Amyloidosis‐associated proteins in the Progression of Alzheimer’s disease
Background: Alzheimer’s disease (AD) is one of the leading causes of death among seniors in the United States and costs the nation over $300 billion each year. Neuropathologically, AD is characterized by neuronal loss, Aβ deposits in the form of plaques, and intracellular aggregates of tau protein in the form of neurofibrillary tangles (NFT). The amyloid cascade hypothesis, one of the leading hypotheses of AD pathogenesis, suggests that Aβ aggregates are directly neurotoxic, triggering downstream neurodegeneration. However, direct evidence supporting the neurotoxicity of Aβ aggregates in vivo is lacking. For example, not all Aβ deposits elicit neurotoxicity. Diffuse plaques are typically negative for Congo‐Red and have very loose shapes and sizes, while neuritic plaques have congophilic cores and are surrounded by swollen neurites. If Aβ is directly neurotoxic, why does Aβ in diffuse plaques not elicit harmful responses while neuritic plaques are associated with neurodegenerative changes? Recent proteomic and transcriptomic studies suggest that there are many biologically active proteins that co‐accumulate with amyloid plaques, which are termed amyloidosis‐associated proteins (AAP). Most of AAP are signaling molecules, and some, such as APOE and Clusterin, are previously shown to be involved in AD pathophysiology. We evaluated the spatiotemporal distribution of diffuse plaques and neuritic plaques, and spatiotemporal accumulation of AAP in postmortem human AD brains of different AD neuropathological changes.Method: We used immunohistochemistry (IHC) and IF on post‐mortem brain tissue specimens to assess the disease stage and brain region specific distribution of NP and amyloidosis associated proteins in cases with low, intermediate and high AD neuropathological changes. In addition, we also use spatial biology to analyze protein level differences in different Aß plaque types.Result: We identified brain region and disease stage specific differences in the distribution and ratio of NP and other Aß‐deposits and correlated these findings with local microglia activation and co‐depositing proteins.Conclusion: Characterization and quantification of neuritic plaque and co‐depositing proteins in different brain regions and AD stages will guide effective therapeutic treatment for Alzheimer’s disease.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e092565
Open AccessAccumulation of Novel Amyloidosis‐associated proteins in the Progression of Alzheimer’s disease
Background: Alzheimer’s disease (AD) is one of the leading causes of death among seniors in the United States and costs the nation over $300 billion each year. Neuropathologically, AD is characterized by neuronal loss, Aβ deposits in the form of plaques, and intracellular aggregates of tau protein in the form of neurofibrillary tangles (NFT). The amyloid cascade hypothesis, one of the leading hypotheses of AD pathogenesis, suggests that Aβ aggregates are directly neurotoxic, triggering downstream neurodegeneration. However, direct evidence supporting the neurotoxicity of Aβ aggregates in vivo is lacking. For example, not all Aβ deposits elicit neurotoxicity. Diffuse plaques are typically negative for Congo‐Red and have very loose shapes and sizes, while neuritic plaques have congophilic cores and are surrounded by swollen neurites. If Aβ is directly neurotoxic, why does Aβ in diffuse plaques not elicit harmful responses while neuritic plaques are associated with neurodegenerative changes? Recent proteomic and transcriptomic studies suggest that there are many biologically active proteins that co‐accumulate with amyloid plaques, which are termed amyloidosis‐associated proteins (AAP). Most of AAP are signaling molecules, and some, such as APOE and Clusterin, are previously shown to be involved in AD pathophysiology. We evaluated the spatiotemporal distribution of diffuse plaques and neuritic plaques, and spatiotemporal accumulation of AAP in postmortem human AD brains of different AD neuropathological changes.Method: We used immunohistochemistry (IHC) and IF on post‐mortem brain tissue specimens to assess the disease stage and brain region specific distribution of NP and amyloidosis associated proteins in cases with low, intermediate and high AD neuropathological changes. In addition, we also use spatial biology to analyze protein level differences in different Aß plaque types.Result: We identified brain region and disease stage specific differences in the distribution and ratio of NP and other Aß‐deposits and correlated these findings with local microglia activation and co‐depositing proteins.Conclusion: Characterization and quantification of neuritic plaque and co‐depositing proteins in different brain regions and AD stages will guide effective therapeutic treatment for Alzheimer’s disease.
- Open Access
- 23 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4580
Dopamine Release Neuroenergetics in Mouse Striatal Slices
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Dopamine (DA) neurons in the substantia nigra pars compacta, which have axonal projections to the dorsal striatum (dSTR), degenerate in PD. In contrast, DA neurons in the ventral tegmental area, with axonal projections to the ventral striatum, including the nucleus accumbens (NAcc) shell, are largely spared. This study aims to uncover the relative contributions of glycolysis and oxidative phosphorylation (OxPhos) to DA release in the striatum. We measured evoked DA release in mouse striatal brain slices using fast-scan cyclic voltammetry applied every two minutes. Blocking OxPhos resulted in a greater reduction in evoked DA release in the dSTR when compared to the NAcc shell, while blocking glycolysis caused a more significant decrease in evoked DA release in the NAcc shell than in the dSTR. Furthermore, when glycolysis was bypassed in favor of direct OxPhos, evoked DA release in the NAcc shell decreased by approximately 50% over 40 min, whereas evoked DA release in the dSTR was largely unaffected. These results demonstrate that the dSTR relies primarily on OxPhos for energy production to maintain evoked DA release, whereas the NAcc shell depends more on glycolysis. Consistently, two-photon imaging revealed higher oxidation levels of DA terminals in the dSTR than in the NAcc shell. Together, these findings partly explain the selective vulnerability of DA terminals in the dSTR to degeneration in PD.
- 23 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4580
Open AccessDopamine Release Neuroenergetics in Mouse Striatal Slices
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Dopamine (DA) neurons in the substantia nigra pars compacta, which have axonal projections to the dorsal striatum (dSTR), degenerate in PD. In contrast, DA neurons in the ventral tegmental area, with axonal projections to the ventral striatum, including the nucleus accumbens (NAcc) shell, are largely spared. This study aims to uncover the relative contributions of glycolysis and oxidative phosphorylation (OxPhos) to DA release in the striatum. We measured evoked DA release in mouse striatal brain slices using fast-scan cyclic voltammetry applied every two minutes. Blocking OxPhos resulted in a greater reduction in evoked DA release in the dSTR when compared to the NAcc shell, while blocking glycolysis caused a more significant decrease in evoked DA release in the NAcc shell than in the dSTR. Furthermore, when glycolysis was bypassed in favor of direct OxPhos, evoked DA release in the NAcc shell decreased by approximately 50% over 40 min, whereas evoked DA release in the dSTR was largely unaffected. These results demonstrate that the dSTR relies primarily on OxPhos for energy production to maintain evoked DA release, whereas the NAcc shell depends more on glycolysis. Consistently, two-photon imaging revealed higher oxidation levels of DA terminals in the dSTR than in the NAcc shell. Together, these findings partly explain the selective vulnerability of DA terminals in the dSTR to degeneration in PD.
- Open Access
- 19 April 2022
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 10 (1) , 1-16
Impact of APOE genotype on prion-type propagation of tauopathy
Apolipoprotein (APOE) is a major risk factor of Alzheimer’s disease (AD), with the E2, E3 and E4 isoforms differentially regulating the burden of AD-associated neuropathologies, such as amyloid β and tau. In AD, pathological tau is thought to spread along neuroanatomic connections following a prion-like mechanism. To provide insights into whether APOE isoforms differentially regulate the prion properties of tau and determine trans-synaptic transmission of tauopathy, we have generated human P301S mutant tau transgenic mice (PS19) that carry human APOE (APOE2, APOE3 or APOE4) or mouse Apoe allele. Mice received intrahippocamal injections of preformed aggregates of K18-tau at young ages, which were analyzed 5 months post-inoculation. Compared to the parental PS19 mice with mouse Apoe alleles, PS19 mice expressing human APOE alleles generally responded to K18-tau seeding with more intense AT8 immunoreactive phosphorylated tau athology. APOE3 homozygous mice accumulated higher levels of AT8-reactive ptau and microgliosis relative to APOE2 or APOE4 homozygotes (E3 > E4~2). PS19 mice that were heterozygous for APOE3 showed similar results, albeit to a lesser degree. In the timeframe of our investigation, we did not observe significant induction of argentophilic or MC1-reactive neurofibrillary tau tangle in PS19 mice homozygous for human APOE. To our knowledge, this is the first comprehensive study in rodent models that provides neuropathological insights into the dose-dependent effect of APOE isoforms on phosphorylated tau pathology induced by recombinant tau prions.
- 19 April 2022
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 10 (1) , 1-16
Open AccessImpact of APOE genotype on prion-type propagation of tauopathy
Apolipoprotein (APOE) is a major risk factor of Alzheimer’s disease (AD), with the E2, E3 and E4 isoforms differentially regulating the burden of AD-associated neuropathologies, such as amyloid β and tau. In AD, pathological tau is thought to spread along neuroanatomic connections following a prion-like mechanism. To provide insights into whether APOE isoforms differentially regulate the prion properties of tau and determine trans-synaptic transmission of tauopathy, we have generated human P301S mutant tau transgenic mice (PS19) that carry human APOE (APOE2, APOE3 or APOE4) or mouse Apoe allele. Mice received intrahippocamal injections of preformed aggregates of K18-tau at young ages, which were analyzed 5 months post-inoculation. Compared to the parental PS19 mice with mouse Apoe alleles, PS19 mice expressing human APOE alleles generally responded to K18-tau seeding with more intense AT8 immunoreactive phosphorylated tau athology. APOE3 homozygous mice accumulated higher levels of AT8-reactive ptau and microgliosis relative to APOE2 or APOE4 homozygotes (E3 > E4~2). PS19 mice that were heterozygous for APOE3 showed similar results, albeit to a lesser degree. In the timeframe of our investigation, we did not observe significant induction of argentophilic or MC1-reactive neurofibrillary tau tangle in PS19 mice homozygous for human APOE. To our knowledge, this is the first comprehensive study in rodent models that provides neuropathological insights into the dose-dependent effect of APOE isoforms on phosphorylated tau pathology induced by recombinant tau prions.